Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI chatbot could spot breast cancer genes from family history

NCT ID NCT07070128

Diagnosis Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study is testing an artificial intelligence tool that collects family cancer history through WhatsApp to predict genetic risk of breast cancer. Researchers will enroll 800 women already identified as high-risk by their doctors and compare the AI's predictions with standard genetic test results. The goal is to see if the AI can reliably identify who needs genetic counseling, potentially making risk assessment more accessible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI tool could help identify women at high genetic risk for breast cancer more easily, potentially leading to earlier genetic counseling and testing.
What could go wrong
This is an observational study, not a treatment trial. The AI tool may not be accurate enough to replace standard genetic testing, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Convenience sampling will be performed, inviting all women treated at both institutions from January 2017 to June 2024 who have been considered by breast surgeons as genetic risk patients and have undergone genetic testing with a geneticist, regardless of whether they have invasive breast carcinoma.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * female patients, * aged 18 years or older, * identified as high genetic risk by breast surgeons, * referred to a geneticist, and * who agree to participate in the study. Exclusion Criteria: * male patients, * absence of complete information in the medical records, * patients unaware of their biological family history, and * patients who do not agree to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    WITHDRAWN

    Golania, Goiás, 74605-020, Brazil

  • Research Site

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-001, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.